Requires the FDA to issue an interim final rule within one year that replaces references to "animal" testing with "nonclinical" testing across its drug and biologic regulations, and makes the rule effective immediately.

• Directs the Secretary of Health and Human Services, through the FDA Commissioner, to publish an interim final rule not later than 1 year after enactment.
• Replaces "animal" tests, data, studies, models, and research with "nonclinical" terms in listed sections of Title 21 of the Code of Federal Regulations.
• Adds the statutory definition of "nonclinical test" to sections 312.3, 314.3, 315.2, and 601.31 of those regulations.
• Waives the usual notice-and-comment requirement so the interim rule takes effect immediately, and redesignates the second subsection (z) of section 505 of the Federal Food, Drug, and Cosmetic Act as subsection (aa).

• Health, Education, Labor, and Pensions Committee (Senate)

Health